FMR LLC and Abigail P. Johnson reported owning a combined 3,023,434 shares of Camp4 Therapeutics Corp common stock, representing 15.0% of the outstanding class as of 09/30/2025. FMR LLC identifies itself as the filing person and notes that Select Biotechnology Portfolio held 1,463,592 shares, or 7.3%, of the company at that date. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures show the form was executed on 10/06/2025 by an authorized representative.
FMR LLC e Abigail P. Johnson hanno dichiarato di possedere in totale 3,023,434 azioni ordinarie di Camp4 Therapeutics Corp, pari al 15,0% della classe in circolazione al 30/09/2025. FMR LLC si identifica come la persona che presenta la dichiarazione e segnala che Select Biotechnology Portfolio deteneva 1,463,592 azioni, ovvero 7,3%, della società a quella data. La dichiarazione afferma che le azioni sono state acquisite e detenute nell'ordinario svolgimento dell'attività e non per modificare o influenzare il controllo. Le firme mostrano che il modulo è stato eseguito l'06/10/2025 da un rappresentante autorizzato.
FMR LLC y Abigail P. Johnson reportaron poseer un total de 3,023,434 acciones comunes de Camp4 Therapeutics Corp, que representan el 15,0% de la clase en circulación a la fecha de 30/09/2025. FMR LLC se identifica como la persona que presenta la declaración y señala que Select Biotechnology Portfolio poseía 1,463,592 acciones, o 7,3%, de la empresa en esa fecha. La declaración indica que las acciones fueron adquiridas y mantenidas en el curso normal de los negocios y no con el fin de cambiar o influir en el control. Las firmas muestran que el formulario fue ejecutado el 06/10/2025 por un representante autorizado.
FMR LLC와 Abigail P. Johnson은 Camp4 Therapeutics Corp 보통주를 합산 3,023,434주 보유하고 있으며, 이는 당일 발행 주식의 15.0%에 해당합니다. 기준일은 09/30/2025입니다. FMR LLC는 자신을 제출인으로 식별하고 Select Biotechnology Portfolio가 그날 회사의 주식 1,463,592주, 또는 7.3%를 보유했다고 밝힙니다. 제출서는 이 주식이 일반 영업 관행에 따라 취득되어 보유되었으며 지배권 변경이나 영향 목적이 아님을 명시합니다. 서명은 10/06/2025에 공인 대리인이 서명했음을 보여줍니다.
FMR LLC et Abigail P. Johnson ont déclaré posséder un ensemble de 3 023 434 actions ordinaires de Camp4 Therapeutics Corp, représentant 15,0% des actions en circulation au 30/09/2025. FMR LLC s'identifie comme la personne déposante et note que Select Biotechnology Portfolio détenait 1 463 592 actions, soit 7,3% de la société à cette date. Le dépôt précise que les actions ont été acquises et détenues dans le cadre normal des activités et non dans le but de modifier ou d'influencer le contrôle. Les signatures indiquent que le formulaire a été exécuté le 06/10/2025 par un représentant autorisé.
FMR LLC und Abigail P. Johnson meldeten den Besitz von insgesamt 3,023,434 Stammaktien der Camp4 Therapeutics Corp, was 15,0% der ausstehenden Klasse zum Stichtag 09/30/2025 entspricht. FMR LLC identifiziert sich als einreichende Person und gibt an, dass Select Biotechnology Portfolio am selben Datum 1,463,592 Aktien bzw. 7,3% des Unternehmens hielt. Die Einreichung erklärt, dass die Aktien in der üblichen Geschäftstätigkeit erworben und gehalten wurden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle bestimmt seien. Unterschriften zeigen, dass das Formular am 10/06/2025 von einem befugten Vertreter ausgestellt wurde.
أف أم آر LLC وأABELIA P. Johnson أعلنا امتلاك ما مجموعه 3,023,434 سهماً عادياً لشركة Camp4 Therapeutics Corp، وهو يمثل 15.0% من الأسهم القائمة حتى تاريخ 09/30/2025. تُعرّف FMR LLC نفسها كطرف مقدم التقرير وتذكر أن Select Biotechnology Portfolio كانت تملك 1,463,592 سهماً، أو 7.3% من الشركة في ذلك التاريخ. يذكر التقرير أن الأسهم قد تم اكتسابها والاحتفاظ بها في إطار العمل الاعتيادي وليس بغرض تغيير أو التأثير على السيطرة. تظهر التوقيعات أن النموذج تم تنفيذه بتاريخ 10/06/2025 بواسطة ممثل مخول.
Large passive stake disclosed; ownership and voting/dispositive powers are clearly stated.
The filing shows FMR LLC (and Abigail P. Johnson) beneficially hold 3,023,434 shares, representing 15.0% of the class. The reported split indicates sole dispositive power over those shares and approximately 0 shared voting/dispositive power, which clarifies control mechanics.
This holding crosses the regulatory threshold that requires public disclosure and may affect float and trading liquidity in the near term. Investors may watch subsequent filings for any change in percentage ownership or statements that would indicate a different intent than ordinary-course investment within the next few reporting periods.
FMR LLC e Abigail P. Johnson hanno dichiarato di possedere in totale 3,023,434 azioni ordinarie di Camp4 Therapeutics Corp, pari al 15,0% della classe in circolazione al 30/09/2025. FMR LLC si identifica come la persona che presenta la dichiarazione e segnala che Select Biotechnology Portfolio deteneva 1,463,592 azioni, ovvero 7,3%, della società a quella data. La dichiarazione afferma che le azioni sono state acquisite e detenute nell'ordinario svolgimento dell'attività e non per modificare o influenzare il controllo. Le firme mostrano che il modulo è stato eseguito l'06/10/2025 da un rappresentante autorizzato.
FMR LLC y Abigail P. Johnson reportaron poseer un total de 3,023,434 acciones comunes de Camp4 Therapeutics Corp, que representan el 15,0% de la clase en circulación a la fecha de 30/09/2025. FMR LLC se identifica como la persona que presenta la declaración y señala que Select Biotechnology Portfolio poseía 1,463,592 acciones, o 7,3%, de la empresa en esa fecha. La declaración indica que las acciones fueron adquiridas y mantenidas en el curso normal de los negocios y no con el fin de cambiar o influir en el control. Las firmas muestran que el formulario fue ejecutado el 06/10/2025 por un representante autorizado.
FMR LLC와 Abigail P. Johnson은 Camp4 Therapeutics Corp 보통주를 합산 3,023,434주 보유하고 있으며, 이는 당일 발행 주식의 15.0%에 해당합니다. 기준일은 09/30/2025입니다. FMR LLC는 자신을 제출인으로 식별하고 Select Biotechnology Portfolio가 그날 회사의 주식 1,463,592주, 또는 7.3%를 보유했다고 밝힙니다. 제출서는 이 주식이 일반 영업 관행에 따라 취득되어 보유되었으며 지배권 변경이나 영향 목적이 아님을 명시합니다. 서명은 10/06/2025에 공인 대리인이 서명했음을 보여줍니다.
FMR LLC et Abigail P. Johnson ont déclaré posséder un ensemble de 3 023 434 actions ordinaires de Camp4 Therapeutics Corp, représentant 15,0% des actions en circulation au 30/09/2025. FMR LLC s'identifie comme la personne déposante et note que Select Biotechnology Portfolio détenait 1 463 592 actions, soit 7,3% de la société à cette date. Le dépôt précise que les actions ont été acquises et détenues dans le cadre normal des activités et non dans le but de modifier ou d'influencer le contrôle. Les signatures indiquent que le formulaire a été exécuté le 06/10/2025 par un représentant autorisé.
FMR LLC und Abigail P. Johnson meldeten den Besitz von insgesamt 3,023,434 Stammaktien der Camp4 Therapeutics Corp, was 15,0% der ausstehenden Klasse zum Stichtag 09/30/2025 entspricht. FMR LLC identifiziert sich als einreichende Person und gibt an, dass Select Biotechnology Portfolio am selben Datum 1,463,592 Aktien bzw. 7,3% des Unternehmens hielt. Die Einreichung erklärt, dass die Aktien in der üblichen Geschäftstätigkeit erworben und gehalten wurden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle bestimmt seien. Unterschriften zeigen, dass das Formular am 10/06/2025 von einem befugten Vertreter ausgestellt wurde.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CAMP4 THERAPEUTICS CORP
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
13463J101
(CUSIP Number)
09/30/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
13463J101
1
Names of Reporting Persons
FMR LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,022,105.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,023,434.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,023,434.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
15.0 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP No.
13463J101
1
Names of Reporting Persons
Abigail P. Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,023,434.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,023,434.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
15.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CAMP4 THERAPEUTICS CORP
(b)
Address of issuer's principal executive offices:
ONE KENDALL SQUARE,BUILDING 1400 WEST, 3RD FLOOR,CAMBRIDGE,MA,USA,02139
Item 2.
(a)
Name of person filing:
FMR LLC
(b)
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
13463J101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
3023434.00
(b)
Percent of class:
15.0 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
3023434.00
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CAMP4 THERAPEUTICS CORP. The interest of Select Biotechnology Portfolio, in the COMMON STOCK of CAMP4 THERAPEUTICS CORP, amounted to 1463592.00 shares or 7.3% of the total outstanding COMMON STOCK at 09/30/2025.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
10/06/2025
Abigail P. Johnson
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:
10/06/2025
Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
What stake did FMR LLC report in Camp4 Therapeutics (CAMP)?
FMR LLC reported beneficial ownership of 3,023,434 shares, equal to 15.0% of Camp4 Therapeutics common stock as of 09/30/2025.
How many shares did Select Biotechnology Portfolio hold in CAMP?
Select Biotechnology Portfolio held 1,463,592 shares, representing 7.3% of the outstanding common stock at 09/30/2025.
Does the filing say FMR LLC intends to change control of Camp4 (CAMP)?
The filing certifies the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control.
What voting and dispositive powers were reported by FMR LLC for CAMP shares?
The filing reports sole voting power of 3,022,105 shares and sole dispositive power of 3,023,434 shares, with 0 shared voting or dispositive power.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
